In confirmed FIGO stage I-IIA endometrial endometrioid carcinomas, using survivin, p21, and p53 as combined biomarkers has a stronger prognostic value than classical parameters, either alone or combined [51 ]. This evidence concerns the gene TP53 and endometrial endometrioid carcinoma.